Systematic Review of Safety of RTS,S with AS01 and AS02 Adjuvant Systems Using Data from Randomized Controlled Trials in Infants, Children, and Adults.

IF 3.1 Q2 PHARMACOLOGY & PHARMACY
Clinical Pharmacology : Advances and Applications Pub Date : 2023-03-14 eCollection Date: 2023-01-01 DOI:10.2147/CPAA.S400155
Wubetu Yihunie, Bekalu Kebede, Bantayehu Addis Tegegne, Melese Getachew, Dehnnet Abebe, Yibeltal Aschale, Habtamu Belew, Bereket Bahiru
{"title":"Systematic Review of Safety of RTS,S with AS01 and AS02 Adjuvant Systems Using Data from Randomized Controlled Trials in Infants, Children, and Adults.","authors":"Wubetu Yihunie,&nbsp;Bekalu Kebede,&nbsp;Bantayehu Addis Tegegne,&nbsp;Melese Getachew,&nbsp;Dehnnet Abebe,&nbsp;Yibeltal Aschale,&nbsp;Habtamu Belew,&nbsp;Bereket Bahiru","doi":"10.2147/CPAA.S400155","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Emergence of antimalarial drugs and insecticides resistance alarms scientists to develop a safe and effective malaria vaccine. A pre-erythrocytic malaria vaccine called RTS,S has made great strides.</p><p><strong>Aim: </strong>The review was aimed to assess the safety of the candidate malaria vaccine RTS,S with AS01 and AS02 adjuvants using data from Phase I-III randomized controlled clinical trials (RCTs).</p><p><strong>Methods: </strong>This systematic review was conducted based on PRISMA 2020. Regardless of time of publication year, all articles related with safety of RTS,S, RCTs published in the English language were included in the study. The last search of databases, and registry was conducted on 30 May, 2022. Pubmed, Google Scholar, Cochrane Library, Wiley Online Library, and Clinical trials.gov were thoroughly searched for accessible RCTs on the safety of RTS,S malaria vaccine. The studies were screened in three steps: duplicate removal, title and abstract screening, and full-text review. The included studies' bias risk was assessed using the Cochrane risk of bias tool for RCTs. This systematic review is registered at Prospero (registration number: CRD42021285888). The qualitative descriptive findings from the included published studies were reported stratified by clinical trial phases.</p><p><strong>Findings: </strong>A total of thirty-five eligible safety studies were identified. Injection site pain and swelling, febrile convulsion, fever, headache, meningitis, fatigue, gastroenteritis, myalgia, pneumonia, reactogenicity, and anemia were the most commonly reported adverse events. Despite few clinical trials reported serious adverse events, none of them were related to vaccination.</p><p><strong>Conclusion: </strong>Most of the adverse events observed from RTS,S/AS01 and RTS,S/AS02 malaria vaccines were reported in the control group and shared by other vaccines. Hence, the authors concluded that both RTS,S/AS01 and RTS,S/AS02 malaria vaccines are safe.</p>","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":"15 ","pages":"21-32"},"PeriodicalIF":3.1000,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/aa/cpaa-15-21.PMC10024506.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology : Advances and Applications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CPAA.S400155","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Emergence of antimalarial drugs and insecticides resistance alarms scientists to develop a safe and effective malaria vaccine. A pre-erythrocytic malaria vaccine called RTS,S has made great strides.

Aim: The review was aimed to assess the safety of the candidate malaria vaccine RTS,S with AS01 and AS02 adjuvants using data from Phase I-III randomized controlled clinical trials (RCTs).

Methods: This systematic review was conducted based on PRISMA 2020. Regardless of time of publication year, all articles related with safety of RTS,S, RCTs published in the English language were included in the study. The last search of databases, and registry was conducted on 30 May, 2022. Pubmed, Google Scholar, Cochrane Library, Wiley Online Library, and Clinical trials.gov were thoroughly searched for accessible RCTs on the safety of RTS,S malaria vaccine. The studies were screened in three steps: duplicate removal, title and abstract screening, and full-text review. The included studies' bias risk was assessed using the Cochrane risk of bias tool for RCTs. This systematic review is registered at Prospero (registration number: CRD42021285888). The qualitative descriptive findings from the included published studies were reported stratified by clinical trial phases.

Findings: A total of thirty-five eligible safety studies were identified. Injection site pain and swelling, febrile convulsion, fever, headache, meningitis, fatigue, gastroenteritis, myalgia, pneumonia, reactogenicity, and anemia were the most commonly reported adverse events. Despite few clinical trials reported serious adverse events, none of them were related to vaccination.

Conclusion: Most of the adverse events observed from RTS,S/AS01 and RTS,S/AS02 malaria vaccines were reported in the control group and shared by other vaccines. Hence, the authors concluded that both RTS,S/AS01 and RTS,S/AS02 malaria vaccines are safe.

Abstract Image

Abstract Image

使用婴儿、儿童和成人随机对照试验数据对RTS,S与AS01和AS02佐剂系统的安全性进行系统评价。
背景:抗疟药物和杀虫剂耐药性的出现提醒科学家开发安全有效的疟疾疫苗。一种名为RTS,S的红细胞前疟疾疫苗取得了长足的进步。目的:本综述旨在利用I-III期随机对照临床试验(RCTs)的数据评估含有AS01和AS02佐剂的候选疟疾疫苗RTS,S的安全性。方法:本系统综述基于PRISMA 2020进行。无论发表年份何时,所有以英语发表的与RTS、S、RCT安全性相关的文章都被纳入研究。数据库和注册表的最后一次搜索于2022年5月30日进行。Pubmed、Google Scholar、Cochrane Library、Wiley Online Library和Clinical trials.gov对RTS,S疟疾疫苗安全性的随机对照试验进行了彻底搜索。研究分三个步骤进行筛选:删除重复、标题和摘要筛选以及全文审查。纳入研究的偏倚风险使用随机对照试验的Cochrane偏倚风险工具进行评估。该系统审查在Prospero注册(注册号:CRD42021285888)。纳入的已发表研究的定性描述性结果按临床试验阶段分层报告。研究结果:共确定了35项符合条件的安全性研究。注射部位疼痛和肿胀、热性惊厥、发烧、头痛、脑膜炎、疲劳、肠胃炎、肌痛、肺炎、反应原性和贫血是最常见的不良事件。尽管很少有临床试验报告严重不良事件,但没有一项与疫苗接种有关。结论:RTS,S/AS01和RTS,S/AC02疟疾疫苗的不良反应大多发生在对照组,并与其他疫苗共享。因此,作者得出结论,RTS,S/AS01和RTS,S/AC02疟疾疫苗都是安全的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.60
自引率
0.00%
发文量
14
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信